SCHEDULE: Robert Disbrow Reports 7% Stake in Eupraxia Pharma

Robert Disbrow has filed an amended Schedule 13G, reporting a beneficial ownership of 7.0% in Eupraxia Pharmaceuticals Inc. as of September 30, 2025.

Summary

• Robert Disbrow, a Canadian citizen, reported beneficial ownership of 3,568,150 Common Shares of Eupraxia Pharmaceuticals Inc.
• This represents 7.0% of the issuer's outstanding Common Shares.
• The ownership calculation is based on 50,598,331 outstanding Common Shares as of September 30, 2025, plus 200,000 Preferred Shares, as reported in the Issuer's Form 6-K filed on November 4, 2025.
• The reported shares include 3,068,150 Common Shares and 200,000 Common Shares underlying Series 1 preferred shares jointly owned with Kim Kawaguchi.
• An additional 300,000 Common Shares are held by the Disbrows' children, though Robert Disbrow disclaims beneficial ownership of these shares.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide information related to broader industry trends or competitive landscape for Eupraxia Pharmaceuticals Inc.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• The reported beneficial ownership includes shares jointly owned with Kim Kawaguchi, Robert Disbrow's spouse.
• An additional 300,000 Common Shares are held by the Disbrows' children, though Robert Disbrow disclaims beneficial ownership of these shares.

Stakeholder Impact

• This filing informs other shareholders and the market about a significant beneficial owner's stake in the company.
• The disclosure of a 7.0% stake by Robert Disbrow indicates a substantial, long-term interest in the company by an individual.

Next Steps

• NA

Key Dates

Keywords

Eupraxia Pharmaceuticals Inc., Robert Disbrow, Schedule 13G, Beneficial Ownership, Common Shares, Preferred Shares, Shareholder Stake, SEC Filing